• 1
    Saccà L., Fazio S., Longobardi S., Cittadini A. Cardiac effects of growth hormone in physiology and in heart failure. Endocr J 1999;46:S5S10.
  • 2
    Colao A., Marzullo P., Di Somma C, Lombardi G. Growth hormone and the heart. Clin Endocrinol 2001;54:137154.
  • 3
    Böger RH. Nitric oxide and the mediation of the hemodynamic effects of growth hormone in humans. J Endocrinol Invest 1999;22:7581.
  • 4
    Kinugawa S., Tsutsui H., Ide T., et al. Positive inotropic effect of insulin-like growth factor-1 on normal and failing cardiac myocytes. Cardiovasc Res 1999;43:157164.
  • 5
    Tsukahara H., Gordienko DV, Tonshoff B., et al. Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int 1994;45:598604.
  • 6
    Napoli R., Guardasole V., Matarazzo M., et al. Growth hormone corrects vascular dysfunction in patients with heart failure. J Am Coll Cardiol 2002;39:9095.
  • 7
    Giustina A., Volterrani M., Manelli F., et al. Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure. Am Heart J 1999;137:10351043.
  • 8
    Osterziel KJ, Ranke MB, Strohm O., Dietz R. The somatotrophic system in patients with dilated cardiomyopathy: Relation of insulinlike growth factor-1 and its alterations during growth hormone therapy to cardiac function. Clin Endocrinol 2000;53:6168.
  • 9
    Al-Obaidi MK, Hon JKF, Stubbs PJ, et al. Plasma insulin-like growth factor-1 elevated in mild-to-moderate but not severe heart failure. Am Heart J 2001;142:e10.
  • 10
    Broglio F., Fubini A., Morello M., et al. Activity of GH/IGF-I axis in patients with dilated cardiomyopathy. Clin Endocrinol 1999;50:417430.
  • 11
    Anwar A., Gaspoz JM, Pampallona S., et al. Effect of congestive heart failure on the insulin-like growth factor-1 system. Am J Cardiol 2002;90:14021405.
  • 12
    Anker SD, Volterrani M., Pflaum C-D, et al. Acquired growth hormone resistance in patients with chronic heart failure: Implications for therapy with growth hormone. J Am Coll Cardiol 2001;38:443452.
  • 13
    Hambrecht R., Schulze PC, Gielen S., et al. Reduction of insulinlike growth factor-I expression in the skeletal muscle of noncachectic patients with chronic heart failure. J Am Coll Cardiol 2002;39:11751181.
  • 14
    Mangieri E., Croce CT, Tanzilli G., et al. Growth hormone and insulin-like growth factor 1 in normopituitaric patients with various degrees of heart failure. Ann N Y Acad Sci 1995;752:429431.
  • 15
    Corbalan R., Acevedo M., Godoy I., et al. Enalapril restores depressed circulating insulin-like growth factor 1 in patients with chronic heart failure. J Card Fail 1998;4:115119.
  • 16
    Shen Y-T, Woltmann RF, Appleby S., et al. Lack of beneficial effects of growth hormone treatment in conscious dogs during development of heart failure. Am J Physiol 1998;274:H456H466.
  • 17
    Lee W-L, Chen J-W, Ting C-T, et al. Insulin-like growth factor I improves cardiovascular function and suppresses apoptosis of cardiomyocytes in dilated cardiomyopathy. Endocrinology 1999;140:48314840.
  • 18
    Freeman LM, Rush JE, Kehayia JJ, et al. Nutritional alterations and the effect of fish oil supplementation in dogs with heart failure. J Vet Intern Med 1998;12:440448.
  • 19
    Pedersen HD, Häggström J., Olsen LH, et al. Idiopathic asymptomatic thrombocytopenia in Cavalier King Charles Spaniels is an autosomal recessive trait. J Vet Intern Med 2002;16:169173.
  • 20
    Pedersen HD, Schütt T., Søndergaard R., et al. Decreased plasma concentration of nitric oxide metabolites in dogs with untreated mitral regurgitation. J Vet Intern Med 2003;17:178184.
  • 21
    Haggstrom J., Hansson K., Kvart C., et al. Effects of naturally acquired decompensated mitral valve regurgitation on the renin-angio-tensin-aldosterone system and atrial natriuretic peptide concentration in dogs. Am J Vet Res 1997;58:7782.
  • 22
    Renehan AG, Jones J., O'Dwyer ST, Shalet SM. Determination of IGF-I, IGF-II, IGFBP-2, and IGFBP-3 levels in serum and plasma: Comparisons using the Bland-Altman method. Growth Horm IGF Res 2003;13:341346.
  • 23
    Delafontaine P., Lou H., Harrison DG, Bernstein KE. Sequence of a cDNA encoding dog insulin-like growth factor I. Gene 1993;130:305306.
  • 24
    Frey RS, Hathaway MR, Dayton WR. Comparison of the effectiveness of various procedures for reducing or eliminating insulinlike growth factor-binding protein interference with insulin-like growth factor-I radioimmunoassays on porcine sera. J Endocrinol 1994;140:229237.
  • 25
    Plaut K., Cohick WS, Bauman DE, Baxter RC. Evaluation of interference by insulin-like growth factor I (IGF-I) binding proteins in a radioimmunoassay for IGF-I in serum from dairy cows. Domest Anim Endocrinol 1991;8:393405.
  • 26
    Riis PM, Nielsen MO, Jacobsen J. Effect of lactation, pregnancy and somatotropin treatment on plasma IGF-1 concentrations, IGF-1 partition between binding protein groups and binding protein pattern in goats. Acta Agric Scand A-AN 1998;48:1927.
  • 27
    Cornell CC, Kittleson MD, Torre PD, et al. Allometric scaling of M-mode cardiac measurements in normal adult dogs. J Vet Intern Med 2004;18:311321.
  • 28
    Delafontaine P., Brink M. The growth hormone and insulin-like growth factor 1 axis in heart failure. Ann Endocrinol (Paris) 2000;61:2226.
  • 29
    Serneri GGN, Boddi M., Cecioni I., et al. Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function. Circ Res 2001;88:961968.
  • 30
    Eigenmann JE, Patterson DF, Zapf J., Froesch ER. Insulin-like growth factor I in the dog: A study in different dog breeds and in dogs with growth hormone elevation. Acta Endocrinol (Copenhagen) 1984;105:294301.
  • 31
    Khan AS, Sane DC, Wannenburg T., Sonntag WE. Growth hormone, insulin-like growth factor-1 and the aging cardiovascular system. Cardiovasc Res 2002;54:2535.
  • 32
    Tivesten Å, Caidahl K., Kujacic V., et al. Similar cardiovascular effects of growth hormone and insulin-like growth factor-I in rats after experimental myocardial infarction. Growth Horm IGF Res 2001;11:187195.
  • 33
    Isgaard J., Bergh C-H, Caidahl K., et al. A placebo-controlled study of growth hormone in patients with congestive heart failure. Eur Heart J 1998;19:17041711.
  • 34
    Osterziel KJ, Strohm O., Schuler J., et al. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 1998;351:12331237.
  • 35
    Osterziel KJ, Blum WF, Strohm O., Dietz R. The severity of chronic heart failure due to coronary artery disease predicts the endocrine effects of short-term growth hormone administration. J Clin Endocrinol Metab 2000;85:15331539.
  • 36
    Acevedo M., Corbalán R., Chamorro G., et al. Administration of growth hormone to patients with advanced cardiac heart failure: Effects upon left ventricular function, exercise capacity, and neurohormonal status. Int J Cardiol 2003;87:185191.
  • 37
    Speakman JR, Booles D., Butterwick R. Validation of dual energy X-ray absorptiometry (DXA) by comparison with chemical analysis of dogs and cats. Int J Obes 2001;25:439447.
  • 38
    Lauten SD, Cox NR, Brawner WR Jr, Baker HJ. Use of dual energy X-ray absorptiometry for non-invasive body composition measurements in clinically normal dogs. Am J Vet Res 2001;62:12951301.
  • 39
    de Laforcade AM, Freeman LM, Rush JE. Serum nitrate and nitrite in dogs with spontaneous cardiac disease. J Vet Intern Med 2003;17:315318.